Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis

Kynurenic acid (KYNA) is an endogenous antagonist of N-methyl-D-aspartate and α7 nicotinic acetylcholine receptors that is derived from astrocytes as part of the kynurenine pathway of tryptophan degradation. Evidence suggests that abnormal KYNA levels are involved in the pathophysiology of schizophrenia. However, this has never been assessed through a meta-analysis. A literature search was conducted through Ovid using Embase, Medline, and PsycINFO databases (last search: December 2016) with the search terms: (kynuren* or KYNA) and (schizophreni* or psychosis). English language studies measuring KYNA levels using any method in patients with schizophrenia and healthy controls (HCs) were identified. Standardized mean differences (SMDs) were calculated to determine differences in KYNA levels between groups. Subgroup analyses were separately performed for nonoverlapping participant samples, KYNA measurement techniques, and KYNA sample source. The influences of patients' age, antipsychotic status (%medicated), and sex (%male) on study SMDs were assessed through a meta-regression. Thirteen studies were deemed eligible for inclusion in the meta-analysis. In the main analysis, KYNA levels were elevated in the patient group. Subgroup analyses demonstrated that KYNA levels were increased in nonoverlapping participant samples, and centrally (cerebrospinal fluid and brain tissue) but not peripherally. Patients' age, %medicated, and %male were each positively associated with study SMDs. Overall, KYNA levels are increased in patients with schizophrenia, specifically within the central nervous system. An improved understanding of KYNA in patients with schizophrenia may contribute to the development of novel diagnostic approaches and therapeutic strategies.

[1]  Daya Luo,et al.  TDO as a therapeutic target in brain diseases , 2016, Metabolic Brain Disease.

[2]  A. Graff-Guerrero,et al.  Elevated Myo-Inositol, Choline, and Glutamate Levels in the Associative Striatum of Antipsychotic-Naive Patients With First-Episode Psychosis: A Proton Magnetic Resonance Spectroscopy Study With Implications for Glial Dysfunction. , 2016, Schizophrenia bulletin.

[3]  R. Schwarcz,et al.  Astrocytes as Pharmacological Targets in the Treatment of Schizophrenia , 2016 .

[4]  R. Schwarcz,et al.  Kynurenines and Glutamate: Multiple Links and Therapeutic Implications. , 2016, Advances in pharmacology.

[5]  P. Girardi,et al.  Xanthurenic Acid Activates mGlu2/3 Metabotropic Glutamate Receptors and is a Potential Trait Marker for Schizophrenia , 2015, Scientific Reports.

[6]  M. Schwarz,et al.  The role of inflammation in schizophrenia , 2015, Front. Neurosci..

[7]  P. Verhoest,et al.  Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway. , 2015, Journal of medicinal chemistry.

[8]  P. McGuire,et al.  Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials. , 2015, Schizophrenia bulletin.

[9]  R. Keefe,et al.  Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials , 2015, Molecular Psychiatry.

[10]  R. Schwarcz,et al.  Elevated levels of kynurenic acid during gestation produce neurochemical, morphological, and cognitive deficits in adulthood: Implications for schizophrenia , 2015, Neuropharmacology.

[11]  C. Svensson,et al.  Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia--significance for activation of the kynurenine pathway. , 2015, Journal of psychiatry & neuroscience : JPN.

[12]  O. Howes,et al.  Glutamate and dopamine in schizophrenia: An update for the 21st century , 2015, Journal of psychopharmacology.

[13]  J. Gold,et al.  Influence of kynurenine 3-monooxygenase (KMO) gene polymorphism on cognitive function in schizophrenia , 2014, Schizophrenia Research.

[14]  H. Ball,et al.  Tryptophan-Catabolizing Enzymes – Party of Three , 2014, Front. Immunol..

[15]  Brooke M. Roberts,et al.  Reduction of Brain Kynurenic Acid Improves Cognitive Function , 2014, The Journal of Neuroscience.

[16]  T. Fukushima,et al.  Quantitative Analyses of Schizophrenia-Associated Metabolites in Serum: Serum D-Lactate Levels Are Negatively Correlated with Gamma-Glutamylcysteine in Medicated Schizophrenia Patients , 2014, PloS one.

[17]  K. Fuxe,et al.  Endogenous kynurenic acid regulates extracellular GABA levels in the rat prefrontal cortex , 2014, Neuropharmacology.

[18]  P. Kochunov,et al.  Stress-induced increase in kynurenic acid as a potential biomarker for patients with schizophrenia and distress intolerance. , 2014, JAMA psychiatry.

[19]  N. Barnes,et al.  Cytokine function in medication-naive first episode psychosis: A systematic review and meta-analysis , 2014, Schizophrenia Research.

[20]  R. Schwarcz,et al.  Continuous kynurenine administration during the prenatal period, but not during adolescence, causes learning and memory deficits in adult rats , 2014, Psychopharmacology.

[21]  R. Schwarcz,et al.  Targeting kynurenine aminotransferase II in psychiatric diseases: promising effects of an orally active enzyme inhibitor. , 2014, Schizophrenia bulletin.

[22]  S Cichon,et al.  A genome-wide association study of kynurenic acid in cerebrospinal fluid: implications for psychosis and cognitive impairment in bipolar disorder , 2013, Molecular Psychiatry.

[23]  M. Goiny,et al.  Behavioral disturbances in adult mice following neonatal virus infection or kynurenine treatment – Role of brain kynurenic acid , 2014, Brain, Behavior, and Immunity.

[24]  I. Schuppe-Koistinen,et al.  Imbalanced Kynurenine Pathway in Schizophrenia , 2014, International journal of tryptophan research : IJTR.

[25]  M Slifstein,et al.  Imaging glutamate in schizophrenia: review of findings and implications for drug discovery , 2014, Molecular Psychiatry.

[26]  P. Fusar-Poli,et al.  Antipsychotics' effects on blood levels of cytokines in schizophrenia: A meta-analysis , 2013, Schizophrenia Research.

[27]  A. Lahti,et al.  Increased hippocampal glutamate and volumetric deficits in unmedicated patients with schizophrenia. , 2013, JAMA psychiatry.

[28]  R. Schwarcz,et al.  Targeted Deletion of Kynurenine 3-Monooxygenase in Mice , 2013, The Journal of Biological Chemistry.

[29]  Brian Kirkpatrick,et al.  Inflammation and schizophrenia. , 2013, Schizophrenia bulletin.

[30]  H. Ball,et al.  Indoleamine 2,3-dioxygenase 2 (IDO2) and the kynurenine pathway: characteristics and potential roles in health and disease , 2013, Amino Acids.

[31]  Til Wykes,et al.  Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy. , 2013, The British journal of psychiatry : the journal of mental science.

[32]  T. Stone,et al.  The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders , 2013, British journal of pharmacology.

[33]  R. Schwarcz,et al.  Early developmental elevations of brain kynurenic acid impair cognitive flexibility in adults: Reversal with galantamine , 2013, Neuroscience.

[34]  K. Fuxe,et al.  Kynurenic acid, by targeting α7 nicotinic acetylcholine receptors, modulates extracellular GABA levels in the rat striatum in vivo , 2013, The European journal of neuroscience.

[35]  S. Sheen,et al.  Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. , 2013, Journal of clinical epidemiology.

[36]  Nicholas Stoy,et al.  An expanding range of targets for kynurenine metabolites of tryptophan. , 2013, Trends in pharmacological sciences.

[37]  J. Toldi,et al.  Kynurenines in the CNS: recent advances and new questions , 2012, Nature Reviews Drug Discovery.

[38]  S. Miyamoto,et al.  Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents , 2012, Molecular Psychiatry.

[39]  R. Murray,et al.  Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. , 2012, The American journal of psychiatry.

[40]  B. Bogerts,et al.  Bridging the gap between the immune and glutamate hypotheses of schizophrenia and major depression: Potential role of glial NMDA receptor modulators and impaired blood–brain barrier integrity , 2012, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[41]  R. Schwarcz,et al.  Kynurenines in the mammalian brain: when physiology meets pathology , 2012, Nature Reviews Neuroscience.

[42]  Mark Slifstein,et al.  Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. , 2012, Archives of general psychiatry.

[43]  R. Schwarcz,et al.  Pre‐ and postnatal exposure to kynurenine causes cognitive deficits in adulthood , 2012, The European journal of neuroscience.

[44]  M. Holtze,et al.  Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. , 2012, Schizophrenia bulletin.

[45]  A. Myint.  Kynurenines: from the perspective of major psychiatric disorders , 2012, The FEBS journal.

[46]  G. Barker,et al.  Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology , 2012, Molecular Psychiatry.

[47]  O. Andreassen,et al.  Kynurenine 3-monooxygenase polymorphisms: relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls. , 2012, Journal of psychiatry & neuroscience : JPN.

[48]  R. Schwarcz,et al.  Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine , 2011, Psychopharmacology.

[49]  S. Erhardt,et al.  Subchronic elevation of brain kynurenic acid augments amphetamine-induced locomotor response in mice , 2012, Journal of Neural Transmission.

[50]  G. Remington,et al.  Treatment resistant schizophrenia and response to antipsychotics: A review , 2011, Schizophrenia Research.

[51]  H. Steinbusch,et al.  Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naïve and medication-free schizophrenic patients , 2011, Brain, Behavior, and Immunity.

[52]  R. Schwarcz,et al.  Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. , 2011, Schizophrenia bulletin.

[53]  M. Torres-Ramos,et al.  On the antioxidant properties of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress. , 2011, Neurotoxicology and teratology.

[54]  R. Schwarcz,et al.  Fluctuations in Endogenous Kynurenic Acid Control Hippocampal Glutamate and Memory , 2011, Neuropsychopharmacology.

[55]  L Elliot Hong,et al.  Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. , 2011, Archives of general psychiatry.

[56]  A. Graff-Guerrero,et al.  Higher Levels of Glutamate in the Associative-Striatum of Subjects with Prodromal Symptoms of Schizophrenia and Patients with First-Episode Psychosis , 2011, Neuropsychopharmacology.

[57]  J. Lindenmayer,et al.  Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia , 2011, Schizophrenia Research.

[58]  M. Schwarz,et al.  Kynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects. , 2011, Current pharmaceutical design.

[59]  R. Pellicciari,et al.  Cortical kynurenic acid bi-directionally modulates prefrontal glutamate levels as assessed by microdialysis and rapid electrochemistry , 2010, Neuroscience.

[60]  C. J. Omiecinski,et al.  Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[61]  R. Schwarcz,et al.  Reduction of Endogenous Kynurenic Acid Formation Enhances Extracellular Glutamate, Hippocampal Plasticity, and Cognitive Behavior , 2010, Neuropsychopharmacology.

[62]  R. Schwarcz,et al.  Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia. , 2010, Schizophrenia bulletin.

[63]  G. Gerhardt,et al.  Second‐by‐second analysis of alpha 7 nicotine receptor regulation of glutamate release in the prefrontal cortex of awake rats , 2009, Synapse.

[64]  D. Bucci,et al.  L-kynurenine treatment alters contextual fear conditioning and context discrimination but not cue-specific fear conditioning , 2009, Behavioural Brain Research.

[65]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement , 2009, BMJ.

[66]  P. Scully,et al.  Kynurenine pathway in psychosis: evidence of increased tryptophan degradation , 2009, Journal of psychopharmacology.

[67]  K. Larsson,et al.  Elevated levels of kynurenic acid change the dopaminergic response to amphetamine: implications for schizophrenia. , 2009, The international journal of neuropsychopharmacology.

[68]  S. Kapur,et al.  The dopamine hypothesis of schizophrenia: version III--the final common pathway. , 2009, Schizophrenia bulletin.

[69]  R. Schwarcz,et al.  On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo , 2009, Journal of neurochemistry.

[70]  R. Schwarcz,et al.  Specific inhibition of kynurenate synthesis enhances extracellular dopamine levels in the rodent striatum , 2009, Neuroscience.

[71]  R. Conley,et al.  The Effects of Galantamine on Psychopathology in Chronic Stable Schizophrenia , 2009, Clinical neuropharmacology.

[72]  R. Schwarcz,et al.  Astrocyte‐derived kynurenic acid modulates basal and evoked cortical acetylcholine release , 2009, The European journal of neuroscience.

[73]  M. Schwarz,et al.  Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission , 2006, Neurotoxicity Research.

[74]  Christine L Miller.  The evolution of schizophrenia: a model for selection by infection, with a focus on NAD. , 2009, Current pharmaceutical design.

[75]  S. Erhardt,et al.  Pharmacological Manipulation of Kynurenic Acid , 2009, CNS drugs.

[76]  M. Rothermundt,et al.  S100B in schizophrenia: an update. , 2009, General physiology and biophysics.

[77]  R. Schwarcz,et al.  The Astrocyte-Derived α7 Nicotinic Receptor Antagonist Kynurenic Acid Controls Extracellular Glutamate Levels in the Prefrontal Cortex , 2009, Journal of Molecular Neuroscience.

[78]  S. Erhardt,et al.  Clozapine interacts with the glycine site of the NMDA receptor: electrophysiological studies of dopamine neurons in the rat ventral tegmental area. , 2008, Life sciences.

[79]  N. Müller.  Inflammation and the glutamate system in schizophrenia: implications for therapeutic targets and drug development. , 2008, Expert opinion on therapeutic targets.

[80]  S. Erhardt,et al.  Activation of rat ventral tegmental area dopamine neurons by endogenous kynurenic acid: A pharmacological analysis , 2007, Neuropharmacology.

[81]  S. Erhardt,et al.  The kynurenic acid hypothesis of schizophrenia , 2007, Physiology & Behavior.

[82]  R. Schwarcz,et al.  Mitochondrial aspartate aminotransferase: a third kynurenate‐producing enzyme in the mammalian brain , 2007, Journal of neurochemistry.

[83]  R. Schwarcz,et al.  Competitive Antagonism between the Nicotinic Allosteric Potentiating Ligand Galantamine and Kynurenic Acid at α7* Nicotinic Receptors , 2007, Journal of Pharmacology and Experimental Therapeutics.

[84]  D. Bucci,et al.  Elevations of endogenous kynurenic acid produce spatial working memory deficits. , 2007, Schizophrenia bulletin.

[85]  E. Jönsson,et al.  Cerebrospinal fluid kynurenic acid in male patients with schizophrenia – correlation with monoamine metabolites , 2007, Acta Neuropsychiatrica.

[86]  S. Akhondzadeh,et al.  Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial , 2007, Schizophrenia Research.

[87]  E. Jönsson,et al.  Cerebrospinal fluid kynurenic acid in male and female controls - correlation with monoamine metabolites and influences of confounding factors. , 2007, Journal of psychiatric research.

[88]  J. Reagan,et al.  Kynurenic Acid as a Ligand for Orphan G Protein-coupled Receptor GPR35* , 2006, Journal of Biological Chemistry.

[89]  D. Bucci,et al.  Increased concentration of cerebral kynurenic acid alters stimulus processing and conditioned responding , 2006, Behavioural Brain Research.

[90]  R. Schwarcz,et al.  Modulators of the Kynurenine Pathway of Tryptophan Metabolism: Synthesis and Preliminary Biological Evaluation of (S)‐4‐(Ethylsulfonyl)benzoylalanine, a Potent and Selective Kynurenine Aminotransferase II (KAT II) Inhibitor , 2006, ChemMedChem.

[91]  S. Erhardt,et al.  Effects of COX‐1 and COX‐2 inhibitors on the firing of rat midbrain dopaminergic neurons—Possible involvement of endogenous kynurenic acid , 2006, Synapse.

[92]  S. Weis,et al.  Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder , 2006, Brain Research.

[93]  R. Schwarcz,et al.  Kynurenic acid leads, dopamine follows: A new case of volume transmission in the brain? , 2006, Journal of Neural Transmission.

[94]  S. Erhardt,et al.  Subchronic treatment with kynurenine and probenecid: effects on prepulse inhibition and firing of midbrain dopamine neurons , 2006, Journal of Neural Transmission.

[95]  R. Schwarcz,et al.  Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain , 2006, Journal of Neural Transmission.

[96]  K. Blennow,et al.  Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia , 2005, Schizophrenia Research.

[97]  A. Belger,et al.  Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. , 2005, Archives of general psychiatry.

[98]  R. Schwarcz,et al.  Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum , 2005, Journal of neurochemistry.

[99]  D. Hedeker,et al.  Effects of Acute Tryptophan Depletion on Negative Symptoms and Smoking Topography in Nicotine-Dependent Schizophrenics and Nonpsychiatric Controls , 2005, Neuropsychopharmacology.

[100]  J. Lauriello,et al.  Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. , 2005, The American journal of psychiatry.

[101]  S. Erhardt,et al.  Prostaglandin-mediated control of rat brain kynurenic acid synthesis – opposite actions by COX-1 and COX-2 isoforms , 2005, Journal of Neural Transmission.

[102]  Michael F. Green,et al.  Approaching a consensus cognitive battery for clinical trials in schizophrenia: The NIMH-MATRICS conference to select cognitive domains and test criteria , 2004, Biological Psychiatry.

[103]  M. Geyer,et al.  Endogenous kynurenic acid disrupts prepulse inhibition , 2004, Biological Psychiatry.

[104]  R. Yolken,et al.  Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia , 2004, Neurobiology of Disease.

[105]  A. Sherman,et al.  l-Kynurenine Its synthesis and possible regulatory function in brain , 1980, Neurochemical Research.

[106]  J. Lindenmayer.  Treatment Refractory Schizophrenia , 2004, Psychiatric Quarterly.

[107]  S. Erhardt,et al.  Inhibitory Action of Clozapine on Rat Ventral Tegmental Area Dopamine Neurons Following Increased Levels of Endogenous Kynurenic Acid , 2003, Neuropsychopharmacology.

[108]  L. Clerkin,et al.  Micromolar Brain Levels of Kynurenic Acid are Associated with a Disruption of Auditory Sensory Gating in the Rat , 2003, Neuropsychopharmacology.

[109]  Ravi S. Menon,et al.  Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. , 2002, The American journal of psychiatry.

[110]  S. Erhardt,et al.  Increased phasic activity of dopaminergic neurones in the rat ventral tegmental area following pharmacologically elevated levels of endogenous kynurenic acid. , 2002, Acta physiologica Scandinavica.

[111]  K. Blennow,et al.  Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia , 2001, Neuroscience Letters.

[112]  R. Schwarcz,et al.  Increased cortical kynurenate content in schizophrenia , 2001, Biological Psychiatry.

[113]  C. Tamminga,et al.  Effects of Ketamine in Normal and Schizophrenic Volunteers , 2001, Neuropsychopharmacology.

[114]  R. Schwarcz,et al.  The Brain Metabolite Kynurenic Acid Inhibits α7 Nicotinic Receptor Activity and Increases Non-α7 Nicotinic Receptor Expression: Physiopathological Implications , 2001, The Journal of Neuroscience.

[115]  B. Brew,et al.  Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection , 2001, Journal of neurochemistry.

[116]  M. Raiteri,et al.  Presynaptic kynurenate‐sensitive receptors inhibit glutamate release , 2001, The European journal of neuroscience.

[117]  A. Young,et al.  Acute tryptophan depletion in schizophrenia , 2001, Psychological Medicine.

[118]  R. Schwarcz,et al.  The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. , 2001, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[119]  S. Erhardt,et al.  Pharmacological elevation of endogenous kynurenic acid levels activates nigral dopamine neurons , 2001, Amino Acids.

[120]  K. Deepadevi,et al.  Tryptophan and tyrosine catabolic pattern in neuropsychiatric disorders. , 2000, Neurology India.

[121]  S Duval,et al.  Trim and Fill: A Simple Funnel‐Plot–Based Method of Testing and Adjusting for Publication Bias in Meta‐Analysis , 2000, Biometrics.

[122]  A. Belger,et al.  Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions , 2000, Biological Psychiatry.

[123]  A. Malhotra,et al.  Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. , 1999, The American journal of psychiatry.

[124]  A. Cesura,et al.  Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase. , 1997, Journal of medicinal chemistry.

[125]  R W Neufeld,et al.  Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. , 1997, Archives of general psychiatry.

[126]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[127]  J. Davis,et al.  Acute dietary tryptophan depletion: effects on schizophrenic positive and negative symptoms. , 1997, Neuropsychobiology.

[128]  R. Schwarcz,et al.  (R,S)-3,4-dichlorobenzoylalanine (FCE 28833A) causes a large and persistent increase in brain kynurenic acid levels in rats. , 1996, European journal of pharmacology.

[129]  J. Krystal,et al.  Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[130]  Herbert Weingartner,et al.  NMDA Receptor Function and Human Cognition: The Effects of Ketamine in Healthy Volunteers , 1996, Neuropsychopharmacology.

[131]  J. Olney,et al.  Glutamate receptor dysfunction and schizophrenia. , 1995, Archives of general psychiatry.

[132]  J. Hietala,et al.  Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients , 1995, The Lancet.

[133]  Carol A. Tamminga,et al.  Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia , 1995, Neuropsychopharmacology.

[134]  D R Medoff,et al.  Ketamine activates psychosis and alters limbic blood flow in schizophrenia , 1995, Neuroreport.

[135]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[136]  R. Schwarcz,et al.  Blood–Brain Barrier Transport of Kynurenines: Implications for Brain Synthesis and Metabolism , 1991, Journal of neurochemistry.

[137]  G. Lynch,et al.  A Glycine Site Associated with N‐Methyl‐d‐Aspartic Acid Receptors: Characterization and Identification of a New Class of Antagonists , 1989, Journal of neurochemistry.

[138]  C. Grossman,et al.  6,7-Dinitro-quinoxaline-2,3-dion and 6-nitro,7-cyano-quinoxaline-2,3-dion antagonise responses to NMDA in the rat spinal cord via an action at the strychnine-insensitive glycine receptor. , 1988, European journal of pharmacology.

[139]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.

[140]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[141]  R. Schwarcz,et al.  Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid , 1984, Neuroscience Letters.

[142]  T. Stone,et al.  An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid , 1982, Brain Research.

[143]  P. Seeman,et al.  Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. , 1975, Science.

[144]  J. Leklem.  Quantitative aspects of tryptophan metabolism in humans and other species: a review. , 1971, The American journal of clinical nutrition.